SEC Filings
REGENXBIO Loses Royalty Revenue As Patent Expirations Cut Zolgensma Payments By $21.2 Million
A $38.0 million patent-settlement gain helped narrow the quarterly loss as spending on Duchenne trials increased.
RGNX
REGENXBIO (RGNX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
REGENXBIO Chairman Kenneth Mills Resigns From Board After Taking CEO Job Elsewhere
George Migausky, an independent director, becomes Chairman, and Daniel Tassé gives up the lead independent director role.
SEC Filings
JPMorgan Reports 5.3% Passive Stake In REGENXBIO, 3,560,915 Shares, In SEC Filing
The bank's Schedule 13G lists a September 30, 2026 triggering event and sole voting power over 3,324,340 shares.